Skip to content
drillr.ai
Sign up

ENLV

Enlivex Ltd.

NASDAQ · Healthcare · Biotechnology · IL

$1.37
−5.92%
Ask drillr

  • Nov 2, 2026, 13:00 UTC

    Enlivex reported 12-month Phase I/IIa trial data showing a clinically meaningful response in 79.2% of patients aged 64 and older treated with Allocetra, compared with 47.6% in the placebo group.

    Source:

  • Oct 28, 2026, 12:00 UTC

    Enlivex reported that 135 of 182 planned patients had been randomized and received their first Allocetra injection in its Phase 2b knee osteoarthritis trial.

    Source:

  • Oct 22, 2026, 21:16 UTC

    Enlivex Ltd. announced a 1-for-16 reverse split of its ordinary shares, effective October 27, 2026, after which the shares will trade on Nasdaq on a split-adjusted basis.

    Source:

  • Oct 19, 2026, 12:17 UTC

    Enlivex announced a cost-reduction plan effective immediately to reduce cash burn and focus resources on its Phase 2b Allocetra trial for knee osteoarthritis.

    Source:

  • Sep 22, 2026, 12:00 UTC

    Enlivex Ltd. terminated its previously announced financing that was payable in RAIN tokens.

    Source:

  • Jul 31, 2026, 15:25 UTC

    Enlivex, a Nasdaq-listed biotech company, is seeking shareholder approval to authorize up to $800 million in financing, potentially increasing share count by up to 951%, with proceeds primarily used to acquire the RAIN crypto token for treasury purposes.

    Source:

  • Jul 28, 2026, 12:00 UTC

    Enlivex announced a private placement of $400,000,000 of ordinary shares to a single institutional investor.

    Source:

  • Jul 13, 2026, 12:00 UTC

    Enlivex received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra in age-related knee osteoarthritis.

    Source:

  • Jul 7, 2026, 12:00 UTC

    Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026.

    Source: